Drug Profile
Research programme: peptide therapeutic - Ferring Pharmaceuticals/Foresee Pharmaceuticals
Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Foresee Pharmaceuticals
- Developer Ferring Pharmaceuticals; Foresee Pharmaceuticals
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for research development in Unspecified in Taiwan (Parenteral, Injection)
- 28 Mar 2021 No recent reports of development identified for research development in Unspecified in USA (Parenteral, Injection)
- 13 Feb 2017 Ferring Pharmaceuticals in-licenses stabilized injectable formulation depot delivery platform technology from Foresee Pharmaceuticals